Effect of anti-lymphocyte antibody induction therapy on renal allograft survival.


Journal Article (Review)

Our two meta-analyses show that antilymphocyte antibody induction therapy extends allograft survival when compared to induction therapy with cyclosporine, azathioprine, and prednisone with the majority of the benefit seen during the first 2 years after transplant. The benefit of induction therapy with respect to allograft survival is particularly important among patients with pretransplant panel reactive antibodies greater than 20%. Although our understanding of the role of antilymphocyte antibody induction therapy continues to evolve, these two meta-analyses provide evidence for its use in clinical renal transplantation.

Full Text

Cited Authors

  • Szczech, LA; Feldman, HI

Published Date

  • May 1999

Published In

Volume / Issue

  • 31 / 3B Suppl

Start / End Page

  • 9S - 11S

Pubmed Central ID

  • 10330960

Electronic International Standard Serial Number (EISSN)

  • 1873-2623

International Standard Serial Number (ISSN)

  • 0041-1345

Digital Object Identifier (DOI)

  • 10.1016/s0041-1345(99)00094-9


  • eng